MedTrace Logo

Visualizing Beta Cells After Bariatric Surgery

NCT02542059 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2023-12-08

No results posted yet for this study

Summary

In order to evaluate the difference in beta cell mass in patients with and without complete resolution of type 2 diabetes mellitus (T2DM) after Roux en Y gastric bypass (RYGB) investigators aim to compare quantitative PET imaging of the pancreas between these patient groups.

These highly relevant data will provide investigators with more information on the possible role of beta cell mass in the mechanisms behind resolution of T2DM after bariatric surgery. This would be of great interest for the assessment of RYGB as an alternative therapy in patients with T2DM with a BMI \<35, who currently do not meet the international guidelines for bariatric surgery.

Conditions

Interventions

RADIATION

68Ga-exendin PET/CT

68Ga-exendin PET/CT

Sponsors & Collaborators

  • Rijnstate Hospital

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Martin Gotthardt, Prof. Dr. · Radboud University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02542059 on ClinicalTrials.gov